arXivDaily arXiv每日学术速递 周一至周五更新
arXiv周末暂无论文更新,休息一下吧,周末愉快~~
arXiv 2603.29316stat.AP
收藏

一种针对混合类型数据聚类和变量选择的贝叶斯有限混合模型方法:带截断生物标志物

A Bayesian Finite Mixture Model Approach for Mixed-type Data Clustering and Variable Selection with Censored Biomarkers

University of Pittsburgh(匹兹堡大学)

Yueting Wang, Shu Wang, Jonathan G. Yabes, Chung-Chou H. Chang

AI总结:

本文提出一种贝叶斯有限混合模型方法,用于处理混合类型数据的聚类和变量选择,尤其在处理截断生物标志物方面具有优势,通过模拟研究和实际数据集验证其在复杂生物医学数据中的有效性。

摘要:

混合类型数据的聚类仍然是生物医学研究中的重大挑战,旨在从异质患者群体中揭示具有临床意义的亚组。现有聚类方法通常假设局部独立性,无法处理截断生物标志物或无法量化变量重要性。我们提出了一种贝叶斯有限混合模型(BFMM)聚类框架,该框架解决了这些限制。BFMM灵活地建模连续和分类变量,采用三种协方差结构来捕捉簇内连续特征之间的依赖关系,并通过基于似然的插补处理截断观测值。为了促进特征优先级排序,BFMM使用尖峰- slab先验估计变量重要性,其在连续0-1尺度上进行估计。模拟研究证明,BFMM在聚类准确性方面优于现有方法,特别是在簇内相关性强或存在截断变量时,并且在不同条件下可靠地区分信息性特征与噪声。我们将其应用于两个真实世界数据集:(1)整合电子健康记录的SENECA队列,用于研究脓毒症患者;(2)急性肺损伤患者的EDEN随机试验。在两种设置中,BFMM识别了具有临床解释力的表型,并揭示了变量对亚组区别的特定贡献。在EDEN试验中,它还揭示了治疗异质性的证据。这些发现验证了BFMM作为复杂生物医学数据的有效、可解释和实用的聚类工具。

英文摘要:

Clustering mixed-type data remains a major challenge in biomedical research to uncover clinically meaningful subgroups within heterogeneous patient populations. Most existing clustering methods impose restrictive assumptions like local independence, fail to accommodate censored biomarkers, or unable to quantify variable importance. We propose a Bayesian finite mixture model (BFMM) clustering framework that addresses these limitations. BFMM flexibly models both continuous and categorical variables, incorporates three covariance structures to capture cluster-specific dependencies among continuous features, and handles censored observations through likelihood-based imputation. To facilitate feature prioritization, BFMM uses spike-and-slab priors to estimate variable importance on a continuous 0-1 scale. Simulation studies demonstrate that BFMM outperforms existing methods in clustering accuracy, particularly given strong within-cluster correlation or censored variables, and reliably distinguishes informative features from noise under varying conditions. We applied BFMM to two real-world datasets: (1) the SENECA cohort integrating electronic health records from patients with Sepsis; and (2) the EDEN randomized trial of patients with acute lung injury. In both settings, BFMM identified clinically interpretable phenotypes and revealed variable-specific contributions to subgroup differentiation. In the EDEN trial, it also uncovered evidence of treatment heterogeneity. These findings validate BFMM as an effective, interpretable, and practically useful clustering tool for complex biomedical datasets.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑